Mangoceuticals, Inc. — Form 8-K Summary
Event date: October 8, 2026. This filing reports a registered direct offering; it does not provide operating results for a quarterly or annual reporting period.
Offering and key financial terms
- The company agreed to sell 657,000 common shares together with warrants for gross proceeds of approximately $492,750, before offering expenses. The combined price was $0.75 per share-and-warrant package.
- The warrants are immediately exercisable, have a $1.00 exercise price, and expire five years after issuance. They include a cashless exercise feature and beneficial-ownership limits of 4.99%, or 9.99% if elected, subject to a 61-day notice period for an increase.
- The filing describes warrants to purchase up to 657,000 shares and separately refers to up to 788,400 warrant shares. Net proceeds and offering expenses are not quantified.
- Management intends to use net proceeds for working capital and general corporate purposes. No revenue, profit, cash-flow, margin, debt, or liquidity figures are provided.
Changes, outlook, and risks
The offering introduces new common shares and warrants, creating potential dilution. The company reported that closing was expected on or about October 9, subject to customary conditions, and states that it issued a press release announcing the closing on October 9, 2026. No operating guidance or broader business outlook is included.
Important facts to verify
- Confirm the completed closing, final proceeds, and expenses using the October 9 press release and prospectus supplement.
- Reconcile the stated 657,000 warrant shares with the separately stated maximum of 788,400 warrant shares and the cashless-exercise provision.
- Review the warrant form and purchase agreement for full terms, adjustments, and potential dilution.